A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas

Trial Profile

A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MPACT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 06 Jun 2017 Results of development and validation of nomogram to predict OS using baseline patient variables, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 28 Jun 2016 Results of exploratory analysis published in the British Journal of Cancer
    • 16 Apr 2016 Results of subgroup analysis (n=63) published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top